ClinicalTrials.gg
CompletedNCT07123376Updated Aug 14, 2025

Pharmacokinetics, Pharmacodynamics Profile and Tolerance of HRS-9231 in Healthy Subjects

A Phase 1 interventional study of HRS-9231 and Placebo in Healthy Volunteers, sponsored by Shanghai Shengdi Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by Shanghai Shengdi Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Diagnostic

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Jun 2024, registered Aug 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of HRS-9231 injection in a single dose in healthy subjects

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Shanghai Shengdi Pharmaceutical Co., Ltd is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 to 45 years.
  2. (BMI) of 19.0 to 28.0 kg/m2 (inclusive).
  3. Understand in detail the content, procedure and possible adverse effects of the trial, and voluntarily sign the written form (ICF).

Exclusion criteria

Exclusion Criteria:

  1. Patients with for magnetic resonance imaging (MRI) examinations.
  2. During the screening period, those whose 12-lead examination is judged by clinical doctors as abnormal and of clinical significance will be selected.
  3. Those with a history of drug abuse, drug use, or positive results in drug abuse screening.
  4. Unable to tolerate venipunctures or have a history of fainting needles and blood.
  5. People with various urinary disorders (such as frequent urination, difficulty in urination, etc.)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Group 1

    8 healthy subjects were to be included

    Drug: HRS-9231 · Drug: Placebo

  • Experimental
    Group 2

    8 healthy subjects were to be included

    Drug: HRS-9231 · Drug: Placebo

  • Experimental
    Group 3

    8 healthy subjects were to be included

    Drug: HRS-9231 · Drug: Placebo

  • Experimental
    Group 4

    8 healthy subjects were to be included

    Drug: HRS-9231 · Drug: Placebo

  • Experimental
    Group 5

    8 healthy subjects were to be included

    Drug: HRS-9231 · Drug: Placebo

Interventions

  • HRS-9231 was administered intravenously;

  • DrugPlacebo

    Placebo was administered intravenously.

06

What researchers measure

Primary outcomes

  1. Adverse events, serious adverse events

    Time frame: From ICF signing date to Day10

Secondary outcomes

  1. Cmax:maximum concentration measured. Blood samples were taken to assess HRS-9231 concentration

    Time frame: From baseline (1 hour before injection) to 12 hours post-injection

  2. t1/2 = terminal elimination half-life of the compound

    Time frame: From baseline (1 hour before injection) to 12 hours post-injection

  3. Cl = total clearance

    Time frame: From baseline (1 hour before injection) to 12 hours post-injection

07

Study locations

1 site
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Oct 2024, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Aug 14, 2025
StartActual
Jun 5, 2024
Primary completionActual
Oct 6, 2024
CompletionActual
Oct 6, 2024
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07123376
Responsible party
Sponsor
First posted
Aug 14, 2025
Start date
Jun 5, 2024
Primary completion
Oct 6, 2024
Completion
Oct 6, 2024
Last update
Aug 14, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-9231

Start the discussion